How it works:
Idelalisib specifically inhibits the delta isoform of phosphoinositide 3-kinase (PI3K δ), critical in B-cell signalling. This leads to apoptosis and reduced proliferation of cancerous cells. IDEENAT is well-tolerated and offers an oral option for patients who are refractory or intolerant to conventional chemotherapy.
Recommended for:
Chronic lymphocytic leukaemia (CLL), including treatment-resistant forms
Follicular lymphoma after at least two prior therapies
Small lymphocytic lymphoma (SLL)
Patients unsuitable for cytotoxic chemotherapy
Individuals requiring long-term oral cancer therapy
Chronic lymphocytic leukaemia (CLL)
Follicular lymphoma (FL)
Small lymphocytic lymphoma (SLL)
IDEENAT 150mg should be taken orally once or twice daily as directed by a specialist. Swallow the tablet whole with water, regardless of meals. Continuous monitoring is essential throughout the course of treatment to assess liver function, blood counts, and adverse effects.
Hypersensitivity to idelalisib or its excipients
Severe hepatic impairment
Active viral infections including hepatitis B
Pregnancy and breastfeeding
Inflammatory gastrointestinal disorders (e.g., colitis)
Diarrhoea, nausea, abdominal pain
Liver enzyme elevations
Leukopenia, neutropenia
Fatigue, headache
Skin rash, dermatitis
Pneumonitis (rare)
Respiratory and urinary tract infections
